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1.1	Introduction
Purinergic	P2Y	receptors	are	an	important	subclass	of	G-protein	coupled	receptors	and	comprises	of	eight	mammalian	subtypes	(P2Y1,2,4,6,11,12,13	and	14)	which	confer	different	binding	affinities	for	ATP,	ADP,	UTP,	and	UDP	[1].
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Abstract
Previous	research	from	our	laboratory	has	demonstrated	a	novel	phenomenon	whereby	GPCRs	play	a	role	in	inhibiting	cytokine-mediated	c-Jun	N-terminal	kinase	(JNK)	signalling.	So	far	this	novel	phenomenon	seems	to
have	been	vastly	overlooked,	with	 little	 research	 in	 the	area.	Therefore,	 in	 this	 study	we	explored	 this	 further;	by	assessing	 the	potential	 of	P2YRs	 to	mediate	 inhibition	of	 cytokine-mediated	 JNK	signalling	and	 related
functional	 outcomes	 in	 human	 endothelial	 cells.	We	 utilised	 primary	 endothelial	 cells,	 and	 employed	 the	 use	 of	 endogenous	 activators	 of	 P2YRs	 and	 well	 characterised	 pharmacological	 inhibitors,	 to	 assess	 signalling
parameters	mediated	by	P2YRs,	Interleukin-1β	(IL-1β),	TNFα	and	JNK.	Activation	of	P2YRs	with	adenosine	tri-phosphate	(ATP)	resulted	in	a	time-	and	concentration-dependent	inhibition	of	IL-1β-mediated	phosphorylation	of
JNK	and	associated	kinase	activity.	The	effect	was	specific	for	cytokine-mediated	JNK	signalling,	as	ATP	was	without	effect	on	JNK	induced	by	other	non-specific	activators	(e.g.	sorbitol,	anisomycin),	nor	effective	against	other
MAPK	pathways	such	as	p38	and	the	canonical	NFκB	cascade.	Pharmacological	studies	demonstrated	a	role	for	the	P2Y11	receptor	in	mediating	this	effect,	but	not	the	P2Y1	nor	the	adenosine	receptors	(A1,	A2A,	A2B	&	A3).
The	novel	Gαq/11	inhibitor	YM254890	and	a	protein	kinase	A	(PKA)	inhibitor	H89	both	partially	reversed	ATP-mediated	inhibition	of	IL-1β-stimulated	JNK	indicating	involvement	of	both	Gαq/11	and	Gαs	mediated	pathways.	ATP
also	 partially	 reversed	 IL-1β-mediated	 induction	 of	 cyclo‐‑oxygenase-2	 (COX-2)	 and	 E-selectin.	 Collectively,	 these	 studies	 indicate	 the	 potential	 for	 activation	 of	 purinergic	 receptors	 to	 protect	 the	 endothelium	 from
inflammatory	driven	JNK	activation	and	may	be	a	new	target	for	inflammatory	disease	therapy.
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For	example,	the	preferred	agonist	for	P2Y1,12	and	13	is	ADP,	whereas	ATP	and	UTP	are	equipotent	for	P2Y2	and	the	P2Y11	receptor	is	the	only	one	selective	for	ATP	[2].	Of	the	P2Y	subtypes,	P2Y1,	P2Y2,	and	P2Y11	are	predominantly
expressed	in	epithelial	cells	and	play	a	functional	role	in	these	systems	[3].	ATP	was	first	thought	to	be	solely	an	intracellular	energy	source	with	concentrations	of	around	5‐–10 mM	in	the	cytoplasm	of	all	cells;	however	it	soon	became
clear	that	these	intracellular	nucleotides	can	be	released	not	only	following	tissue	injury	but	also	by	non-lytic	mechanisms	through	regulated	transport	[4].
Early	 studies	 recognised	 that	 ATP	 and	 adenosine	 were	 particularly	 important	 in	 the	 mechanisms	 underlying	 local	 control	 of	 vessel	 tone	 [5],	 as	 well	 as	 cell	 migration,	 differentiation	 and	 death	 during	 angiogenesis,
atherosclerosis,	and	restenosis	following	angioplasty		[6,	7].	Extracellular	ATP	has	also	been	shown	to	drive	systemic	 inflammation,	and	 tissue	damage	 in	murine	models	of	LPS-induced	 inflammation	 [8].	More	 recently	purinergic
signalling	has	been	shown	to	play	a	role	in	inflammation	and	cancer,	where	activation	of	P2Y11	inhibits	the	migration	of	tumour	derived	endothelial	cells	via	cAMP	signalling	[9].
The	cellular	actions	of	P2Y1,	P2Y2,	and	P2Y11	have	been	shown	to	be	mediated	through	the	activation	of	a	number	of	key	signalling	pathways.	These	include	the	extracellular	regulated	protein	kinases,	namely	ERK	[1]	and	the
stress-activated	protein	kinases,	p38	MAP	kinase,	and	c-Jun	N-terminal	kinase	 (JNK)	 [10,	11],	however,	 the	exact	mechanisms	 involved	 in	P2YR	activation	of	 these	pathways	are	still	not	 fully	understood.	 In	Human	umbilical	vein
endothelial	cells	(HUVECs),	activation	of	P2Y1	leads	to	both	p38	MAPK	and	JNK	phosphorylation	[11].	Of	the	three	subtypes	described	so	far,	P2Y11	is	the	most	abundantly	expressed	in	HUVECs	[3]	and	its	activation	leads	to	both	IP3
and	cAMP	accumulation,	demonstrating	its	interaction	with	both	Gαq/11	and	GαS	[12,	13].
In	previous	 studies	we	uncovered	a	novel	mechanism	of	 regulation	of	 cytokine-mediated	 inflammatory	 signalling	at	 the	 level	 of	 c-Jun	N-terminal	 kinase	 (JNK).	Pre-activation	of	 either	PAR2	or	 the	P2Y2	 receptor	mediates
inhibition	of	TNFα-mediated	JNK	signalling,	thought	to	be	mediated	in	part	by	the	dissociation	of	the	TNFR1	from	receptor	associated	proteins	[14–16].	However	these	studies	were	conducted	in	clonal	cell	lines	expressing	high	levels
of	receptor	and	it	is	unclear	if	this	applies	to	endogenous	levels	of	receptor	or	has	a	functional	consequence.
Therefore,	in	this	study	we	examined	the	potential	for	endogenous	P2Y	receptor	activation	to	mediate	inhibition	of	cytokine-stimulated	JNK	signalling	in	cultures	of	primary	endothelial	cells.
2.2	Material	and	Mmethods
2.1.2.1	Materials
All	materials	used	were	of	the	highest	commercial	grade	available	and	were	purchased	from	Sigma-Aldrich	(Dorset,	UK)	unless	otherwise	stated.	The	P2Y11	receptor	antagonist,	NF340	(pIC50	6.43	and	7.14	in	Ca2+	and	cAMP
respectively,	[17])	and	the	P2Y1	receptor	antagonist,	MRS2179	(KB = 100 nM,	[18])	were	obtained	from	Tocris	Bioscience	(R&D	Systems	Europe,	Ltd.,	Abingdon,	UK).	The	ecto-nucleotidase	inhibitor,	ARL67156	(pIC50 = 4.62	in	human
blood,	[19]),	the	A2A	antagonist	ZM241385	(pIC50 = 9.52,	[20]),	the	protein	kinase	A	(PKA)	inhibitor,	H89	(IC50 = 135 nM,	[21])	and	the	EPAC	activator,	8-CPT-2Me-cAMP	(EC50 = 2.2,	[22])	were	all	from	Tocris	bioscience	(R&D	Systems
Europe,	Ltd.,	Abingdon,	UK).	Antibodies	raised	against	phosphorylated	 forms	of	 JNK	(Thr	183/Tyr	185)	and	p65	(Ser	536)	were	 from	New	England	Biolabs	 (England,	UK)	and	p38	MAP	kinase	(pTpY	180/182)	was	purchased	from
Invitrogen	(Paisley,	UK).	Anti-IκBα,	anti-JNK,	anti-p65	and	p38	MAP	kinase	antibodies	were	obtained	from	Santa	Cruz	Biotechnology	(CA,	USA).	The	horse	radish	peroxidase	HRP-coupled	secondary	antibodies	were	manufactured	by
Jackson	Immuno	research	and	distributed	from	Stratech	Scientific	(Suffolk,	UK).	Tumour	necrosis	factor-α	(TNFα)	and	interleukin-1-β	(IL-1β)	were	purchased	from	Insight	Biotechnology	(Middlesex,	UK).	The	YM-254890	compound	[23]
was	a	kind	gift	of	Astellas	Pharma.	Inc.,	Japan.	The	Human	sE-selectin	ELISA	kit	was	purchased	from	Invitrogen	(Paisley,	UK).
2.2.2.2	Cell	Cculture
HUVECs	(Lonza,	UK,	*CC-2519)	were	grown	in	endothelial	basal	media,	supplemented	with	endothelial	growth	media	(EGM-2)	containing	single	aliquots	(2%	foetal	bovine	serum,	0.2 ml	hydrocortisone,	2 ml	hFGF-B,	0.5 ml
VEGF,	0.5 ml	R3-insulin	like	growth	factor-1,	0.5 ml	ascorbic	acid,	0.5 ml	hEGF,	0.5 ml	GA	1000,	0.5 ml	heparin	*CC-3162)	and	were	purchased	from	Lonza,	UK	(Each	aliquot	of	cryopreserved	HUVECs	consisted	of	3	pooled	donors,	and	3
vials	were	used	in	total	for	duration	of	experiments,	9	donors).	Human	coronary	artery	endothelial	cells	(HCAECs)	(Promocell,	Heidelberg)	were	grown	in	endothelial	cell	growth	medium	MV2	supplemented	with	5%	foetal	calf	serum,
5 ng/ml	hEGF,	10 ng/ml	hBFGF,	20 ng/ml	insulin-like	growth	factor,	0.5 ng/ml	hVEGF,	1	ug μg/ml	ascorbic	acid	and	0.2	ug μg/ml	hydrocortisone	(each	aliquot	of	cryopreserved	HCAECs	were	from	a	single	donor).	All	experiments	were
performed	between	passages	2	and	6.	MDA-MB-231	cells	(ECACC,	cat:	9202042A)	were	maintained	in	DMEM	supplemented	with	penicillin	(250 units/ml),	streptomycin	(100	μg/ml),	L-glutamine	(27 mg/ml)	and	foetal	calf	serum	at	10%
(v/v).	Cells	were	utilised	between	passages	10	and	20.	All	cells	were	kept	in	a	humidified	atmosphere	containing	5%	CO2	at	37°C.
2.3.2.3	Western	blotting
Proteins	were	separated	by	10%	SDS–PAGE	and	transferred	onto	nitrocellulose.	The	membranes	were	blocked	for	non-specific	binding	for	2 	hrh.	in	2%	Bovine	serum	albumin	(w/v)	diluted	in	a	sodium	tris-tween	(NATT)	buffer
(50 mM	Tris–HCl,	150 mM	NaCl,	0.02%	(v/v)	Tween-20).	The	blots	were	then	incubated	overnight	with	50 ng/ml	primary	antibody	diluted	 in	0.2%	BSA	(w/v)	 in	NATT	buffer.	The	blots	were	washed	with	NATT	buffer	 for	90 min	and
incubated	with	HRP-conjugated	secondary	antibody	(20 ng/ml	in	0.2%	BSA	(w/v)	diluted	in	NATT	buffer)	for	2 	hrh.	After	a	further	90 min	wash,	the	blots	were	subjected	to	enhanced	chemiluminescence	reagent	and	exposed	to	Kodak	X-
ray	film.
2.4.2.4	JNK	Aactivity	Aassay
To	measure	 JNK	activity,	cells	were	stimulated	as	appropriate	and	 the	reaction	 terminated	by	rapid	aspiration	and	 the	cell	monolayer	washed	with	 ice-cold	PBS.	The	cells	were	solubilised	 in	20 mM	HEPES	buffer,	pH 7.7,
containing	50 mM	NaCl,	0.1 mM	EDTA,	0.1 mM	Na3VO4,	0.1 mM	PMSF,	10	μg/ml	aprotinin,	10	μg/ml	leupeptin,	and	1%	(w/v)	Triton	X-100.	Lysates	were	clarified	by	centrifugation	for	5 min	at	13,000 rpm	and	equal	amounts	of	protein
were	incubated	with	20 μg	of	GST-c-Jun-(5–89)	 immobilized	on	glutathione-Sepharose	at	4 °C	for	3 	hrh.	Beads	were	 then	washed	 three	 times	 in	 solubilisation	buffer	and	 twice	 in	25 mM	HEPES	buffer,	pH 7.6,	containing	20 mM	 β-
glycerophosphate,	0.1 mM	NaV3O4,	2 mM	dithiothreitol.	Precipitates	were	then	incubated	with	the	same	buffer	containing	25	μM/1.85	x	 × 1010 Bq	of	ATP/	[γ
32P]	ATP	 in	 a	 final	 volume	 of	 30	μl	 at	 30 °C	 for	 30 min.	 The	 reactions	were	 terminated	 by	 the	 addition	 of	 4	 x	 SDS-sample	 buffer	 and	 aliquots	 of	 each	 sample	 subjected	 to	 electrophoresis	 on	 11%	SDS-PAGE.	 Phosphorylation	 of
GST-c-Jun	was	then	determined	by	autoradiography.
2.5.2.5	ELISA
To	measure	E-selectin	expression,	HUVECs	were	stimulated	as	appropriate	and	the	reaction	terminated	by	rapid	aspiration	and	the	cells	solubilised	 in	20 mM	HEPES	buffer,	pH 7.7,	containing	50 mM	NaCl,	0.1 mM	EDTA,
0.1 mM	Na3VO4,	0.1 mM	PMSF,	10	μg/ml	aprotinin,	10	μg/ml	leupeptin,	and	1%	(w/v)	Triton	X-100.	Lysates	were	clarified	by	centrifugation	and	supernatants	used	immediately	or	stored	at	-20o °C.	ELISAs	were	performed	according	to
manufactures	guidelines	(Human	sE-selectin	ELISA	kit	-	Invitrogen).	Briefly,	micro-wells	coated	with	an	anti-E-selectin	monoclonal	antibody	were	washed	prior	to	the	addition	of	sample	diluent,	and	standard	dilutions	were	prepared	in
duplicate	through	a	range	of	serial	dilutions	(1.6 ng/ml	to	50 ng/ml).	Cell	supernatant	samples	were	added	in	duplicate	and	diluted	1:5	with	sample	diluent	and	mixed	thoroughly.	An	HRP-conjugated	anti-E-selectin	antibody	was	then
added	to	all	micro-wells	and	strips	incubated	for	2 	hrh.	shaking	at	room-temperature.	Any	unbound	antibody	was	removed	by	a	wash	step	prior	to	the	addition	of	a	HRP-reactive	substrate	solution;	reactions	were	terminated	by	the
addition	of	500 mM	phosphoric	acid	and	absorbance	measured	at	450 nm	on	a	BMG	labtech,	Polarstar	Omega	reader.	The	concentration	of	E-selectin	present	was	determined	using	the	standard	curve	generated.
2.6.2.6	Data	analysis	and	Sstatistical	procedures
Where	experimental	data	is	shown	as	a	blot,	this	represents	one	of	at	least	4	independent	experiments	and	densitometry	data	represents	the	mean	±	SEM.	Statistical	analysis	was	performed	using	Graph-pad	prism	6.0,		using
one-way	ANOVA	with	Dunnett’'s	post-test	(*P <	0 .05,	**P <	0 .01,	***P <	0 .001,	****P <	0 .0001).	EC50	and	IC50	data	was	generated	on	Graph-pad	prism	6,	using	a	sigmoidal	non-linear	regression	curve	with	variable	slope	analysis.
3.3	Results
3.1.3.1	ATP	inhibits	cytokine-driven	JNK	activity
Initially	we	examined	the	potential	for	several	activators	of	endothelial	cell	GPCRs	to	mediate	inhibition	of	JNK	signalling.	This	included	utilising	trypsin,	an	endogenous	activator	of	PAR2	[24],	ATP/UTP	endogenous	activators	of
the	purinergic	receptors	and	histamine	and	endothelin-1.	Of	these	agonists	we	found	that	ATP	was	by	far	the	most	efficacious.
Figure.	1	panel	A	shows	a	concentration-dependent	inhibition	of	IL-1β	driven	JNK	activation,	as	mediated	by	ATP.		Treatment	with	IL-1β	(10 ng/ml)	alone	caused	a	5‐–6	fold	increase	in	JNK	as	assessed	by	either	Western	blotting
for	 phospho-JNK	or	 JNK	activity	 as	measured	by	 in	 vitro	 kinase	 assay.	 	Pre-treatment	with	 increasing	 concentrations	 of	 ATP	 (1‐–100	μM)	 for	 30 min	 substantially	 reduced	 cytokine	mediated	 JNK	 signalling	 by	 approximately	 70%
(kinase = %	stim,	IL-1β	=	100%,	ATP	(100	μM) + IL-1β	=31.11	±	12.73%,	P <	0 .05).		Whilst	pre-incubation	substantially	inhibited	the	response,	co-incubation	with	ATP	(30	μM)	and	IL-1β	(10 ng/ml)	at	30 min	was	less	effective	(Fold	stim	–
IL-1β	=	10.75	±	0.61,	ATP + IL-1β	=	6.68	±	0.86,	P <	0 .01),	suggesting	a	minimal	pre-incubation	time	is	required	to	elicit	a	significant	JNK	inhibitory	response	(Fig.	1B).
A	similar	but	more	potent	effect	to	that	seen	in	panel	A	was	observed	when	TNFα	was	used	as	the	stimulus	in	HUVECs	(Fig.1C).	Where	we	observed	a	concentration-dependent	inhibition	of	JNK	activity	(IC50 = 7.04	μM)	with	as
little	as	10	μM	ATP	abolishing	all	JNK	activity	in	HUVECs	(%	stim,	TNFα	=	100	%,	ATP	(10	μM) + TNFα	=	‐−26.48 ± 17.06	%,	P <	0 .01).
3.2.3.2	Specificity	of	inhibition
The	specificity	of	the	inhibitory	effect	was	further	examined	in	Figure.	2.		In	contrast	to	effects	upon	IL-1β,	ATP	was	ineffective	against	either	sorbitol,	or	anisomycin,	two	non-specific	cellular	stresses,	both	of	which	strongly
Fig.	1	ATP	mediated	inhibition	of	IL-1β-stimulated	JNK	phosphorylation	and	activity	in	HUVECs.
In	Fig.	1A	HUVECs	were	pre-incubated	for	30 min	with	increasing	concentrations	of	ATP	prior	to	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	Samples	were	assayed	for	JNK	activity	and	phosphorylation	as	outlined	in	the	methods	section.	In	Fig.	1B	HUVECs	were
treated	simultaneously	with	ATP	(100	μM)	and	IL-1β	(10 ng/ml)	for	15,	30	and	60 	minutesmin.	In	Fig.	1C	HUVECs	were	pre-incubated	for	30 min	with	increasing	concentrations	of	ATP	prior	to	stimulation	with	TNFα	(10 ng/ml)	for	a	further	30 min.	Samples	were	assayed	for	JNK
activity.	Proteins	were	quantified	from	JNK	activity	assays	(Fig.	1B,	C),	and	both	JNK	assays	and	phospho-blotting	(Fig.	1A).	Each	value	represents	the	mean	±	SEM	from	4	independent	experiments	and	data	was	quantified	by	densitometry.	*P <	0 .05,	**P <	0 .01,	****P <	0 .0001
compared	to	IL-1β	or	TNFα	alone.
alt-text:	Fig.	1
activated	JNK	(kinase:	fold	stim	–	sorbitol	~	20	fold,	anisomycin	~	22	fold),	similar	to	IL-1β	(kinase:	fold	stim	–	IL-1β	~	16	fold)	(Fig.	2A).		Furthermore,	the	effect	of	ATP	was	specific	to	cytokine	–mediated	JNK	signalling.	Whilst	IL-1β
was	able	to	stimulate	the	other	stress-activated	protein	kinase	p38	MAP	kinase	(Fold	stim	–	IL-1β	=	5.42	±	0.68	vs.	control)	this	activity	was	not	significantly	affected	by	ATP	(Fold	stim	-	ATP	(100μM) + IL-1β	=	4.8	±	0.38)	as	shown	in
Figure.	2	panel	B.
Fig.	2	Specificity	of	ATP	mediated	JNK	inhibition	in	HUVECs.
In	Fig.	2A	HUVECs	were	pre-incubated	for	30 min	with	30	and	100	μM	ATP	prior	to	stimulation	with	IL-1β	(10 ng/ml),	sorbitol	(0.5 M)	and	anisomycin	(0.5 μM)	for	a	further	30 min.	Samples	were	assayed	for	JNK	activity	and	phosphorylation.	In	Fig.	2B,	HUVECs	were	incubated
with	increasing	concentrations	of	ATP	(1‐–100μM)	for	30 min	prior	to	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	Phosphorylation	of	p38	MAPK	was	assessed	and	quantified	as	described	in	the	methods	section.	In	Fig.	2C,	HUVECs	were	pre-treated	with	ATP	(100	μM)	for
increasing	time	periods	from	5 	minutesmin	up	to	120 	minutesmin,	before	stimulation	with	IL-1β	(10 ng/ml)	for	30 	minutesmin.	ATP	treatment	alone	at	a	middle	time	point	(60	mins)	was	used	as	a	control	to	show	that	receptor	activation	alone	does	not	induce	JNK	activity.	Samples	were
assayed	for	p65	phosphorylation,	IκBα	degradation	and	proteins	quantified	as	outlined	in	the	methods	section.
This	was	also	similarly	demonstrated	in	our	previous	publications	for	both	PAR2	and	P2Y	receptors	[14,	16].	In	addition,	ATP	was	found	to	have	no	effect	upon	either	IL-1β	stimulated	loss	in	cellular	IκBα	nor	the	phosphorylation
of	p65	(Ser536)	(Fig.	2C),	two	well	recognised	markers	of	canonical	NFκB	activation	[25,	26].
3.3.3.3	ATP	inhibitory	activity	is	not	limited	to	HUVECs
We	decided	to	examine	this	inhibitory	phenomenon	in	other	cells	types,	to	eliminate	the	possibility	that	the	effects	observed	in	HUVECs	were	specific	to	this	cell	type.	In	Figure.	3	panel	A,	we	utilised	another	primary	cell	line,
human	 coronary	 artery	 endothelial	 cells	 and	 similar	 to	 the	 HUVECs	 noted	 a	 concentration	 dependent	 inhibition	 of	 IL-1β	 -	 mediated	 JNK	 activity	 by	 ATP.	 Using	 100	 μM	 ATP	 for	 30 	minutesmin	 pre-treatment	 we	 demonstrated
approximately	45%	 inhibition	of	 IL-1β-mediated	 JNK	kinase	 activity	 and	 approximately	 40%	 inhibition	 of	 JNK	phosphorylation		 (%	 stim,	 IL-1β	=	 100%,	 kinase = ATP	 (100	μM) + IL-1β	=	 54.4 ± 6.4%,	P <	 0 .01	 and	 pJNK = ATP	 (100
μM) + IL-1β	=	60 ± 5.9%	P <	0 .01).
Proteins	were	quantified	from	both	JNK	activity	assays	and	phospho-blotting	(Fig.	2A).	Each	value	represents	the	mean	±	SEM	from	at	least	4	independent	experiments	and	data	was	quantified	by	densitometry.	*P <	0 .05,	**P <	0 .01	compared	to	IL-1β	alone.
alt-text:	Fig.	2
Fig.	3	ATP	mediated	inhibition	of	cytokine-stimulated	JNK	phosphorylation	and	activity	is	also	evident	in	HCAEC	and	MDA-MB-231	cells.
In	Figure.	3	panel	B	we	used	the	human	breast	adenocarcinoma	line	MDA-MB-231	as	an	example	of	a	homogenous	cell	population	to	use	as	a	comparative	to	the	primary	cells	when	examining	levels	of	inhibition.	Here	we	also
observed	a	significant	concentration-dependent	inhibition,	with	30	μM	ATP	giving	an	87%	reduction	in	IL-1β-driven	JNK	activity	(%	stim,	IL-1β	=	100%,	ATP	(30	μM) + IL-1β	=13.28	±	3.6%,	p <	0 .001).	Inhibition	was	observed	as	low	as
1	μM	ATP	where	a	37%	reduction	was	still	evident	before	loss	of	inhibition	at	0.3	μM	ATP.	This	was	true	also	when	TNFα	was	used	as	the	stimulus	in	the	MDA-MB-231	cells	(Fig.	3C)	where	we	again	observed	a	significant	concentration-
dependent	inhibition.	Using	30	μM	ATP	we	observed	an	83%	reduction	 in	TNFα-driven	JNK	activity	(%	stim,	TNFα	=	100%,	ATP	(30	μM) + TNFα	=16.81	±	3.48%,	P <	0 .001)	and	concentrations	as	 low	as	1	μM	ATP	again	showed
significant	inhibition	of	JNK	activity,	with	approximately	46%	reduction.
3.4.3.4	P2YR	subtypes
Endothelium	expresses	a	range	of	purinergic	receptors	including	P2Y1,	2	and	P2Y11	and	the	role	of	these	subtypes	in	the	inhibitory	effect	of	ATP	was	examined	in	Figure.	4.	In	the	absence	of	a	suitable	P2Y2	antagonist	we	tested
the	effect	of	UTP,	a	selective	P2Y2	agonist	and	found	no	significant	inhibition	of	IL-1β-stimulated	JNK	thereby	suggesting	this	receptor	was	not	involved	(data	not	shown).	In	addition,	the	P2Y1	antagonist	MRS2179	was	without	effect	on
either	JNK	activity	or	phosphorylation	as	shown	in	Figure.	4,	panel	A.		In	contrast,	in	Figure.	4	panel	B,	we	found	that	pre-incubation	with	10	μM	of	the	P2Y11	antagonist	NF340	almost	completely	reversed	the	inhibitory	effect	of	ATP	on
IL-1β-induced	JNK	signalling	(%	stim,	IL-1β	=	100%,	ATP + IL-1β	=	20.4%	±	10.8%	and	10	μM	NF + ATP + IL-1β	=	87%	±	8.1%).
In	Fig.	3A	HCAECs	were	pre-incubated	for	30 min	with	increasing	concentrations	of	ATP	prior	to	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	Samples	were	assayed	for	JNK	activity	and	phosphorylation	as	outlined	in	the	methods	section.	In	Fig.	3B	MDA-MB-231	cells
were	pre-incubated	for	30 min	with	increasing	concentrations	of	ATP	prior	to	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min	and	assayed	for	JNK	activity.	In	Fig.	3C,	MDA-MB-231	cells	were	pre-incubated	for	30 min	with	increasing	concentrations	of	ATP	prior	to	stimulation
with	TNFα	(10 ng/ml)	for	a	further	30 min	and	assayed	for	JNK	activity.	Proteins	were	quantified	from	both	JNK	activity	assays	and	phospho-blotting	(Fig.	3A)	and	from	JNK	activity	assays	(Fig.	3B,	C).	Each	value	represents	the	mean	±	SEM	from	at	least	5	experiments	and	data	was
quantified	by	densitometry.	*P <	0 .05,	**P <	0 .01,	***P <	0 .001	compared	to	IL-1β	or	TNFα	alone.
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In	order	 to	 further	confirm	 the	actions	of	ATP	 in	mediating	 JNK	 inhibition	via	 the	P2Y11	 receptor,	we	 investigated	 further	 the	signalling	mechanisms	 involved.	The	P2Y11	 receptor	 couples	 to	Gαq/11	 to	mediate	downstream
signalling	events;	 therefore	we	examined	 the	 role	of	Gαq/11	 as	 shown	 in	Figure.	4	 panel	C.	 Pre-incubation	 of	HUVECs	with	 the	Gαq/11	 inhibitor	 YM254890	 partially	 reversed	 the	 inhibition	 by	ATP	 of	 IL-1β-induced	 JNK	 activity	 and
phosphorylation	at	30	and	100 nM	YM	by	approximately	45%.
3.5.3.5	ATP-mediated	inhibition	of	cytokine-stimulated	JNK	activation	-	specificity	of	P2Y11
The	results	from	Figure.	4,	examining	inhibition	of	Gαq/11,	 suggested	that	another	G-protein	dependent	subunit	may	play	a	role	 in	ATP-mediated	 inhibition	of	 JNK.	 Indeed	P2Y11	couples	to	both	Gαq/11	and	Gαs	 to	mediate	 its
Fig.	4	ATP	mediated	inhibition	of	IL-1β-stimulated	JNK	phosphorylation	and	activity	in	HUVEC	is	via	P2Y11.
In	Fig.	4A,	HUVECs	were	pre-incubated	with	the	P2Y1	antagonist	MRS2179	(10 μM)	for	30 min,	followed	by	ATP	(30 μM)	for	30 min,	and	lastly	IL-1β	(10 ng/ml)	for	30 min.	In	Fig.	4B,	HUVECs	were	treated	with	increasing	concentrations	of	the	P2Y11	antagonist	NF340	prior	to
stimulation	with	30	μM	ATP	for	30 min	followed	by	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	In	Fig.	4C,	HUVECs	were	pre-incubated	for	30 min	with	increasing	concentrations	of	the	Gαq/11	inhibitor	YM254890	prior	to	stimulation	with	30	μM	ATP	for	30 min	followed	by
IL-1β	(10 ng/ml)	for	a	further	30 min.	JNK	activity	was	assessed	by	in	vitro	kinase	assay	(Fig.	4A,	B,	C)	and	phospho-blotting	(Fig.	4A	&	C)	as	outlined	in	the	methods	section.	Statistical	analysis	was	performed	using	one	way	ANOVA	with	Dunnett’'s	post-test.	*P <	0 .05,	**P <	0 .01,
****P	<	0.0001	compared	to	IL-1β	alone,	n.s	–	not	significant	when	compared	to	ATP	and	IL-1β.	Each	value	represents	the	mean	±	SEM	from	4	independent	experiments	and	data	was	quantified	by	densitometry.
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effects;	therefore	we	investigated	the	effect	of	adenosine	which	strongly	stimulates	the	A2A	and	A2B	receptors	via	Gαs	coupling	to	activate	JNK	in	HUVECs.	In	Figure.	5	panel	A,	we	found	that	pre-treatment	with	adenosine	(1‐–100	μM)
lead	to	a	concentration	dependent	inhibition	of	IL-1β-mediated	JNK	signalling,	with	approximately	68%	inhibition	evident	using	100	μM	adenosine	(%	stim,	IL-1β	=	100%,	adenosine+IL-1β	=	32.13%	±	12.21%,	P <	0 .01)	with	an	IC50
value	of	approximately	15	μM	(15.41	±	5.15	μM).	Pre-incubation	with	the	A2A	receptor	antagonist	ZM241385	(10μM),	abolished	the	inhibitory	effect	of	adenosine	(%	stim,	IL-1β	=	100%,	adeno+IL-1β	=	17.9%	±	6.7%,	ZM + adeno+IL-1β
=	103%	±	1.6%,	P <	0 .01),	but	was	without	effect	against	ATP	(Fig.	5B).
Another	possibility	was	that	ATP	may	mediate	its	action	partially	through	the	activation	of	the	adenosine	A2	receptor	due	to	degradation	of	ATP	via	the	ecto-nucleotidase.		The	experiment	in	Figure.	5	panel	C	however	shows	that
Fig.	5	ATP	mediated	inhibition	of	IL-1β-stimulated	JNK	activation	in	HUVECs	does	not	involve	the	adenosine	A2	receptor.
In	Fig.	5A,	HUVECs	were	pre-incubated	for	30 min	with	increasing	concentrations	(1‐–100	μM)	of	adenosine,	followed	by	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	In	Fig.	5B,	HUVECs	were	treated	with	the	A2A	receptor	antagonist	ZM241385	(10	μM)	for	30 min
prior	to	stimulation	with	30	μM	ATP	or	10 μM	adenosine	for	30 min	followed	by	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	In	Fig.	5C,	HUVECs	were	treated	with	increasing	concentrations	(10‐–100	μM)	of	the	ecto-nucleotidase	inhibitor	ARL67156	prior	to	stimulation	with
30	μM	ATP	for	30 min	followed	by	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	Samples	were	assayed	for	JNK	activity	(Fig.	5A,	B	&	C)	and	phosphorylation	(Fig.	5A)	as	outlined	in	the	methods	section.	Proteins	were	quantified	from	both	JNK	activity	assays	and	phospho-
blotting.	Each	value	represents	the	mean	±	SEM	from	5	independent	experiments	and	data	was	quantified	by	densitometry.	**P <	0 .01	compared	to	IL-1β	alone.
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pre-treatment	of	cells	with	the	ecto-nucleotidase	inhibitor,	ARL67156	did	not	result	in	the	reversal	of	the	inhibitory	effect	of	ATP,	which	further	suggests	that	this	mechanism	was	not	involved.
3.6.3.6	G-protein	coupling	of	P2Y11
As	P2Y11	couples	to	both	Gαq/11	and	Gαs	 to	mediate	its	effects	we	decided	to	further	dissect	the	contribution	of	each	pathway	to	the	overall	 inhibition	as	shown	in	Figure.	6.		The	role	of	a	 further	Gαs	 intermediate,	PKA	was
assessed	using	the	pharmacological	inhibitor	of	PKA,	namely	H89.	Pre-treatment	of	the	cells	with	10	μM	H89	(Fig.	6A)	also	partially	reversed	the	effect	of	ATP	by	approximately	36%	(%	stim,	IL-1β	=	100%,	ATP + IL-1β	=	44.42%	±
5.32%,	H89 + ATP + IL-1β	=	80.24%	±	5.14%,	P <	0 .01),	similar	to	that	seen	with	the	Gαq/11	inhibitor	YM254890	(Fig.	4)	indicating	a	possible	contribution	from	Gαs-mediated	PKA	signalling	also.
The	H89	compound	however	also	appeared	to	be	mediating	an	effect	on	IL-1β-mediated	JNK	activation	alone,	lowering	the	response	by	approximately	20%	(Fig.	6A).	Treatment	with	the	H89	compound	did	appear	to	partially
reverse	ATP-mediated	inhibition,	as	the	response	was	brought	back	to	that	of	H89	and	IL-1β	alone	(not	significant).	The	reversal	was	generally	greater	when	the	cells	were	pre-incubated	with	both	compounds	in	combination	(100 nM
YM254890	and	3	μM	H89),	where	a	partial	reversal	of	approximately	60%	was	evident	compared	to	either	16%	reversal	for	YM2548909	or	11%	reversal	for	H89	alone	(Fig.	6B).
3.7.3.7	JNK	mediated	downstream	translational	responses
We	further	sought	to	determine	if	inhibition	of	JNK	by	ATP	was	applicable	to	any	cellular	event	relevant	to	endothelial	cell	pathophysiology.		Figure.	7	shows	the	effect	of	ATP	pre-treatment	on	IL-1β-mediated	induction	of	COX-2
and	the	adhesion	molecules,	ICAM-1	and	VCAM-1.	IL-1β	stimulated	a	concentration-dependent	increase	in	COX-2	expression	(Fig.	7A)	which	reached	maximum	(approximately	8.5	fold	increase	over	basal)	using	10 ng/ml	of	IL-1β	for
8 	hrh.
Fig.	6	Gαs	dependent	mechanisms	also	play	a	role	in	regulating	IL-1β-stimulated	JNK	phosphorylation	and	activity	in	HUVECs.
In	Fig.	6A,	HUVECs	were	treated	with	increasing	concentrations	of	the	PKA	inhibitor	H89,	for	30 min	prior	to	pre-treatment	with	30	μM	ATP	for	a	further	30 min	followed	by	stimulation	with	IL-1β	(10 ng/ml)	for	30 min.	In	Fig.	6B,	HUVECs	were	treated	with	100 nM	YM254890
alone	or	in	combination	with	3	μM	H89	prior	to	stimulation	with	30	μM	ATP	for	30 min	followed	by	stimulation	with	IL-1β	(10 ng/ml)	for	a	further	30 min.	Samples	were	assayed	for	JNK	activity	(Fig.	6A	&	B)	and	phosphorylation	(Fig.	6A)	as	outlined	in	the	methods	section.	Proteins
were	quantified	from	both	JNK	activity	assays	and	phosphoblotting.	Each	value	represents	the	mean	±	SEM	from	at	least	4	independent	experiments	and	data	was	quantified	by	densitometry.	*P <	0 .05,	**P <	0 .01,	***P <0 .001	compared	to	IL-1β	alone.
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In	Figure.	7	panel	B,	pre-treatment	of	the	cells	with	100	μM	ATP	reduced	the	expression	of	COX-2	by	approximately	60%	(%	stim,	IL-1β	=	100%,	ATP + IL-1β	=	45.05%	±	4.39%,	P <	0 .001),	whilst	the	JNK	inhibitor,	SP600125
completely	abolished	expression,	confirming	JNK	regulation	of	COX-2	expression.	In	contrast,	ATP	or	SP600125	did	not	affect	IL-1β	induced	expression	of	ICAM-1	and	VCAM-1,	two	adhesions	molecules	not	known	to	be	regulated	by
JNK	but	rather	NFκB,	thereby	confirming	the	effect	of	ATP	is	selective	to	the	JNK	pathway.	The	expression	of	ICAM-1	and	VCAM-1	as	well	as	COX-2	were	however	sensitive	to	BMS-34551,	an	inhibitor	of	inhibitory	kappa	B	kinases	(Fig.
7B).
In	Figure.	7	panel	C	we	show	that	pre-incubation	with	100 nM	of	the	Gαq/11	inhibitor	YM254890	was	able	to	partially	reverse	the	inhibitory	effect	of	ATP	on	IL-1β-induced	COX-2	expression	by	approximately	25%	(%	stim,	IL-1β	=
Fig.	7	ATP	mediated	inhibition	of	COX-2	expression	in	HUVECs.
In	Fig.	7A,	HUVECs	were	treated	with	increasing	concentrations	of	IL-1β	from	0.1	to	10 ng/ml	for	8 	hrh	and	COX-2	expression	assessed.		In	Fig.	7B,	HUVECs	were	pre-incubated	with	increasing	concentrations	of	ATP	prior	to	stimulation	with	IL-1β	(10 ng/ml),	for	a	further
30 min,	JNK	inhibitor	SP600125	(20	μM)	and	NFκB	inhibitor	BMS-345541	(10	μM)	were	used	as	positive	controls	and	added	30 min	prior	to	IL-1β.	Samples	were	assayed	for	COX-2,	ICAM-1,	and	VCAM-1	expression.	In	Fig.	7C,	HUVECs	were	pre-treated	with	increasing	concentrations
of	the	Gαq/11	inhibitor	YM254890	for	30 min	prior	to	stimulation	with	30	μM	ATP	for	30 min,	followed	by	stimulation	with	IL-1β	for	a	further	30 min.	Samples	were	assayed	for	COX-2	expression	and	NFκB-p65	as	a	loading	control	as	outlined	in	the	methods	section.	Gels	were
quantified	for	protein	expression	(Fig.	7A,	B	&	C).	Each	value	represents	the	mean	±	SEM	from	at	least	4	experiments	and	data	was	quantified	by	densitometry.	**P <	0 .01,	***P <	0 .001	compared	to	IL-1β	alone.
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100%,	ATP + IL-1β	=	65.78%	±	3.99%,	YM + ATP + IL-1β	=	89.08%	±	4.28%,	P <	0 .001).	However,	when	the	PKA	inhibitor	H89	was	used	in	similar	types	of	experiment	a	near	complete	reversal	of	IL-1β-induced	COX-2	expression	was
observed	with	H89	alone,	suggesting	a	prominent	role	for	Gαs	(data	not	shown).
3.8.3.8	ATP	inhibits	IL-1β-driven	E-selectin	expression
In	addition	we	also	examined	another	JNK	dependent	cellular	protein,	E-selectin	which	is	expressed	predominantly	on	the	cell	membrane	and	plays	a	key	role	in	inflammation.	In	Figure.	8	we	demonstrate	the	effect	of	ATP	pre-
treatment	on	the	expression	of	E-selectin.	IL-1β	was	shown	to	stimulate	a	strong	concentration-	and	time-dependent	increase	in	E-selectin	expression	in	HUVECs	with	maximal	expression	at	4 h	post	treatment	(data	not	shown).	We
show	in	Figure.	8	panel	A,	 that	pre-treatment	of	 the	cells	with	ATP	reduced	the	expression	of	E-selectin	 in	response	to	 IL-1β	by	approximately	44%	(IL-1β	=	24.9 ng/ml	±	1.7,	ATP + IL-1β	=	13.3 ng/ml	±	 1.5).	 Interestingly,	 the	 JNK
inhibitor,	SP600125	also	reduced	IL-1β-mediated	E-selectin	expression	by	approximately	44%	(SP + ATP + IL-1β	=	13.4 ng/ml	±	1.0),	thus	suggesting	that	ATP	was	indeed	inhibiting	JNK-mediated	expression	of	E-selectin	in	HUVECs
(Fig.	8A).
In	Figure.	8	panel	B,	the	effect	of	the	Gαq/11	inhibitor,	YM254890	on	ATP	mediated	inhibition	of	E-selectin	was	examined.	While	again,	ATP	was	consistent	in	reducing	IL-1β-mediated	E-selectin	expression	(approximately	80%
inhibition	from	IL-1β	alone),	Gαq/11	did	not	appear	to	have	a	role	in	reversing	this	effect.	The	YM	compound	did	however	have	a	small	effect	on	IL-1β-mediated	E-selectin	expression	alone	(IL-1β	=	8.8 ng/ml	±	0.4,	YM + IL-1β = 6.4 ng/ml
±	2.1),	although	this	was	not	significant	it	suggests	the	potential	that	Gαq/11	pathways	may	mediate	IL-1β	signalling	in	endothelial	cells.
Fig.	8	IL-1β	induction	of	E-selectin	is	regulated	by	ATP	in	HUVECs.
In	Fig.	8A,	HUVECs	were	treated	with	the	JNK	inhibitor	–	SP600125	(10	μM)	for	120 min	alone,	or	30 min	prior	to	pre-treatment	with	30	μM	ATP	for	a	further	30 min,	cells	were	then	stimulated	with	10 ng/ml	of	IL-1β	for	60 min.	Cells	were	lysed	and	supernatants	assayed	for	E-
selectin	expression.	In	Fig.	8B,	HUVECs	were	treated	with	the	Gαq/11	inhibitor	YM254890	(100 nM)	for	30 min	prior	to	pre-treatment	with	ATP	(30	μM)	for	a	further	30 min,	this	was	followed	by	stimulation	with	IL-1β	(10 ng/ml)	for	60 min.	Cells	were	lysed	and	supernatants	assayed
for	E-selectin	expression	as	outlined	in	the	methods	section.	Results	were	graphed	as	expression	of	E-selectin	(ng/ml)	as	determined	from	a	standard	curve.	Results	are	representative	of	6	independent	experiments,	data	calculated	as	mean	±	SEM,	*P <	0 .05,	**P <	0 .01	compared	to
IL-1β	alone.
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4.4	Discussion
In	this	study	we	describe	the	potential	for	ATP	to	inhibit	cytokine-mediated	signalling	in	primary	cultures	of	endothelial	cells.	Indeed	pre-treatment	with	ATP	reduced	cytokine-mediated	signalling	in	a	time-	and	concentration-
dependent	manner	mediated	principally	via	the	P2Y11	receptor	and	did	not	involve	degradation	to	adenosine	as	part	of	the	inhibition	mechanism.	Our	findings	support	and	extend	our	previous	studies	which	highlight	the	potential	for
receptors	linked	to	Gαq/11	to	mediate	a	selective	inhibition	of	JNK	signalling	but	also	indicated	Gαs	dependent	signalling	maybe	involved.	We	also	demonstrated	for	the	first	time	for	this	phenomenon	to	be	relevant	to	JNK	dependent
outcomes	pertinent	to	inflammation,	namely	COX-2	and	E-selectin,	which	are	involved	in	the	pathophysiology	of	the	endothelium.
Within	the	primary	endothelial	cell	environment,	we	believe	varying	levels	of	receptor	expression	across	cell	passages	and	batches	used	for	the	duration	of	the	study	may	be	the	reason	for	the	slight	inconsistency	seen	in	the
levels	of	inhibition	throughout	these	studies;	this	was	true	also	when	using	the	HCAECs.	In	comparison	levels	of	inhibition	observed	using	a	standard	cell	line	MDA-MB-231	remained	consistent.	Receptor	expression	was	not	measured
directly	as	P2Y11	antibodies	have	been	shown	to	lack	specificity,	and	mRNA	expression	in	many	cases	does	not	correlate	to	protein	expression	[27].	Despite	these	variations	within	the	primary	endothelial	cells,	the	salient	point	was	that
statistically	significant	inhibition	was	always	evident	with	ATP	pre-treatment	in	all	experiments.
A	key	consideration	to	this	study	is	the	levels	of	ATP	present	within	the	endothelium.	It	is	well	recognised	that	endothelial	cells	release	substantial	quantities	of	ATP	during	injury	[28]	and	inflammation	[29,	30].	With	ATP	at	the
endothelial	surface	reported	to	be	approximately	14	μM	[31].	However	further	studies	have	demonstrated	that	concentrations	of	extracellular	ATP	released	from	injured	cells	could	reach	125	μM	at	the	moment	of	cell	 injury	[32].
Similarly,	a	study	by	Pellegatti	and	colleagues	measuring	extracellular	ATP	in	vivo	have	reported	concentrations	in	the	hundreds	micromolar	range	in	tumour	interstitium	[33].	Thus	such	levels	are	consistent	with	the	concentrations
required	to	initiate	inhibition	in	this	study.
The	 inhibitory	actions	of	ATP	was	 specific	 to	 cytokine	mediated	 JNK	activation	 rather	 than	a	general	 inhibition	of	 JNK	per	 se,	 as	pre-treatment	had	no	effect	upon	 stress	 induced	 JNK	activation	mediated	by	 sorbitol	 and
anisomycin.	This	suggests	a	phenomenon	consistent	with	previous	findings	from	our	laboratory	but	also	complements	a	previous	study	which	shows	that	activation	of	the	histamine	H1	receptor	was	able	to	inhibit	TNFα-	and	thrombin-
mediated	activation	of	both	p38	MAP	kinase	and	JNK	pathways	[34].		In	addition,	other	GPCRs	such	as	the	cannabinoid	CB2	receptor	have	also	been	shown	to	inhibit	cytokine	mediated	JNK	activity	in	human	coronary	artery	smooth
muscle	cells	[35].	In	this	present	study	we	show	inhibition	to	be	largely	specific	to	JNK	suggesting	cell	type	specific	differences	in	GPCR	driven	inhibition	of	cytokine	mediated	activation	of	MAPK	pathways.
Further	characterisation	revealed	a	role	for	P2Y11	since	the	inhibitory	response	was	sensitive	to	the	P2Y11	selective	antagonist	NF340,	[17].	This	is	in	contrast	to	our	previous	studies	which	implicated	the	involvement	of	P2Y2
receptors	in	mediating	inhibition	of	TNFα	and	sorbitol	stimulated	JNK	and	p38	MAPK	activity	[16].		Different	endothelial	cell	types	vary	in	their	P2YR	expression	profiles	with	HUVECs	predominantly	expressing	P2Y11	receptors	but
additionally	P2Y1	and	P2Y2	[3].	We	also	tested	P2Y1	inhibition	using	the	P2Y1	antagonist	MRS2179	and	showed	no	effect	on	ATP	mediated	inhibition	of	IL-1β	driven	JNK	activity.	We	decided	to	investigate	treatment	with	MRS2179	alone
or	in	combination	with	the	P2Y11	antagonist	NF340,	but	did	not	observe	any	synergistic	effects	 (data	not	shown).	This	 is	pertinent	to	recent	studies	that	reveal	dimerisation	between	P2Y1	and	P2Y11	 receptors	are	required	for	the
internalisation	of	the	P2Y11	receptor	[36].
As	well	as	acting	directly	with	cognate	receptors,	ATP	can	be	degraded	by	a	number	of	membrane	bound	ATPases	resulting	in	the	formation	of	metabolites	such	as	ADP,	AMP	and	adenosine	[37].	Indeed	we	found	that	adenosine
caused	a	concentration	dependent	inhibition	of	JNK	suggesting	this	as	a	potential	mechanism.	Nevertheless,	even	though	the	recognised	kinetics	of	ATP	degradation,	which	is	significant	within	30 min	[38],	occurs	well	within	the	time
span	of	the	experiments	in	this	study,	neither	the	ectoATPase	inhibitor	nor	the	adenosine	A2A	inhibitor	reversed	the	inhibition	of	JNK	mediated	by	ATP,	precluding	this	as	a	mechanism	of	activation.
We	have	previously	 demonstrated	 the	 involvement	 of	Gαq/11	 in	 PAR2-mediated	 inhibition	 of	 TNFα	 -stimulated	 JNK	phosphorylation	 and	 activation	 [14].	 	We	demonstrated	 here	 for	 endogenously	 expressed	 P2Y11	 a	 similar
dependency	using	the	novel	Gαq/11	inhibitor	YM254890	[23,	39].	However,	unlike	our	previous	study	the	reversal	was	only	partial	in	response	to	IL-1β,	suggesting	the	potential	of	a	Gαq/11	independent	effect.	P2Y11	 is	 linked	to	both
Gαq/11	and	Gαs	suggesting	the	possibility	of	the	Gαs	axis	as	an	additional	component.		Indeed,	adenosine	in	engaging		the	A2A	receptor	mediates	its	effects	via	Gαs	[40]	and	also	in	this	study	caused	a	significant	inhibition	of	JNK.	We
found	that	the	PKA	inhibitor	H89	was	able	to	partially	reverse	ATP	mediated	inhibition	suggesting	an	additional	role	for	this	pathway	and	one	which	may	or	may	not	predominate.	This	is	in	keeping	with	a	number	of	studies	which	show
that	Gαs	linked	receptors	can	also	mediate	an	inhibition	of	JNK	signalling,	for	example,	the	Dopamine	D2	receptor	[41],	but	is	in	contrast	to	earlier	studies	linking	Gαs	coupled	receptors	to	the	activation	of	JNK	[42].
A	key	additional	component	to	this	work	was	the	potential	for	ATP	mediated	JNK	inhibition	to	have	consequences	further	downstream	linked	to	the	expression	of	inflammatory	mediators.	We	demonstrated	that	ATP	was	able	to
inhibit	the	induction	of	COX-2	in	response	to	IL-1β,	an	effect	which	could	be	almost	completely	reversed	by	Gαq/11	inhibition.		In	contrast,	the	PKA	inhibitor	H89	alone	abolished	COX-2	induction	suggesting	possible	off-target	effects	of
this	inhibitor,	and	making	interpretation	and	deduction	of	the	role	of	the	Gαs	pathway	in	COX-2	induction	difficult.	H89	has	been	shown	to	inhibit	at	least	8	other	kinases	[21],	therefore	further	studies	examining	the	role	of	Gαs	would
be	required	to	explore	this	further.
A	number	of	studies	demonstrate	that	COX-2	expression	in	the	endothelium	is	indeed	dependent	upon	JNK	[43–45]	and	in	this	current	study	we	show	that	induction	was	sensitive	to	the	JNK	inhibitor	SP600125.		As	a	corollary
we	tested	effects	on	ICAM-1	and	VCAM-1,	two	NFκB	dependent	genes	[46]	and	found	no	ATP	mediated	inhibition	suggesting	that	the	inhibitory	effect	of	ATP	pre-treatment	was	consistent	with	JNK	inhibition	and	not	a	general	one.
Whilst	the	role	of	COX-2	in	endothelial	cell	inflammation	is	controversial,	studies	have	demonstrated	JNK	dependent	up-regulation	of	COX-2	in	atherosclerotic	lesions	[47]	proposed	to	mediate	the	activation	of	the	EP4	receptor	via
prostaglandin	E2	(PGE2)	release	leading	to	secretion	of	inflammatory	mediators	[48,	49].	Our	studies	however	imply	a	functional	effect	of	COX-2,	with	induction	in	endothelial	cells	mediated	by	pro-inflammatory	cytokines,	but	with	the
potential	to	be	down-regulated	via	purinergic	receptor	signalling.	COX-2	induction	however,	may	also	be	cytoprotective	and	inhibition	of	expression	may	be	deleterious	to	endothelial	integrity	[50,	51].
The	role	of	E-selectin	in	endothelial	cell	inflammation	is	well	established,	for	example	the	local	release	of	cytokines	such	as	IL-1β	and	TNFα	by	damaged	cells	induces	the	over-expression	of	E-selectin	on	endothelial	cells	of
nearby	blood	vessels.	This	increased	expression	acts	to	mediate	leukocyte	adhesion	and	recruitment	to	sites	of	injury,	which	is	also	prevalent	during	shear	stress	of	blood	flow,	leading	to	leukocyte	rolling	along	the	blood	vessel	walls
[52].	Studies	have	demonstrated	a	role	for	endothelium-derived	nitric	oxide	(NO)	in	inhibiting	cytokine	mediated	expression	of	E-selectin,	VCAM-1	and	ICAM-1	via	NFκB	signalling,	thereby	preventing	recruitment	of	leukocytes	to	the
vessel	wall	thus	suggesting	another	paradigm	whereby	the	endothelium		confers	protection	against	inflammatory	events	[53].
Another	study	has	shown	a	role	for	adenosine	in	inhibiting	both	cytokine	release	and	expression	of	adhesion	molecules,	including	E-selectin	in	HUVECs,	however	they	could	not	demonstrate	a	clear	role	for	adenosine	receptors
nor	did	they	investigate	ATP	[54].	This	study	therefore	is	the	first	of	its	kind	to	demonstrate	a	role	for	ATP	in	inhibiting	IL-1β-mediated	E-selectin	expression	in	human	primary	endothelial	cells.	This	would	be	of	particular	importance	to
the	endothelium,	as	a	reduction	in	E-selectin	expression	would	limit	the	recruitment	of	immune	cells	and	associated	pro-inflammatory	mediator	release,	thereby	reducing	the	damage	at	the	endothelial	surface.
5.5	Conclusions
This	 study	 develops	 further	 the	 initial	 phenomena	 uncovered,	 showing	 a	 role	 for	GPCRs	 in	modulating	 pro-inflammatory	 cytokine	 signalling.	 This	 also	 starts	 to	 reveal	 the	 functions	 of	 the	 P2Y11	 receptor	which	 has	 been
historically	difficult	to	research	and	characterise	fully		due	to	a	lack	of	murine	models,	effective	antibody	reagents	to	aid	detection	and	functional	methods	[27].	Taken	together	these	results	highlight	the	importance	of	the	purinergic
receptors,	in	particular	P2Y11,	in	mediating	a	protective	role	against	cytokine	induced	stress-activated	signalling	in	the	endothelium.
Indeed	the	potential	for	GPCRs	to	mediate	inhibition	of	cytokine	driven	JNK	signalling	has	a	number	of	 implications.		It	could	be	envisaged	that	ATP	release	mediated	for	example	by	endothelial	distention	or	stretch	could
dampen	down	inflammation	thus	limiting	the	potential	for	initiation	of	plaque	formation	[55].	Thus,	developing	agonists	which	could	activate	endothelial	cell	GPCRs	or	directly	activate	either	Gαq/11	or	Gαs	may	be	of	clinical	potential	in
the	context	of	inflammatory-based	conditions.
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